For all press and media enquiries please contact mediarelations@chiesi.com
Chiesi Group, the largest international pharmaceutical company certified B Corp, reinforce s 2035 carbon neutral target with #ActionOverWords campaign to encourage measurable sustainability commitments and invite accountability. Parma (Italy), 10 May, 2021 – Chiesi Group, the international…
Maria Paola Chiesi, former Coordinator of the Foundation since 2010, succeeds Dr Paolo Chiesi. She is supported by Massimo Salvadori, Coordinator of the Chiesi Foundation since February. Parma, May 3 2021 – On May 1 Maria Paola Chiesi was appointed President of the Chiesi Foundation, a non-profit…
Chronic obstructive pulmonary disease (COPD) patients for whom a dry powder inhaler device is preferred, can now benefit from an extrafine formulation fixed triple combination therapy containing an inhaled corticosteroid (ICS) / long-acting?2-agonist (LABA) / long-acting muscarinic antagonist (LAMA)…
New visual identity is the first public manifestation of Chiesi Group’s continued transformation as a B Corp certified business Patients’ experiences and perception of Chiesi at the heart of the new corporate identity Parma (Italy), March 22, 2021 – Chiesi, the international research-focused…
The Chiesi Group currently employs 6,389 people worldwide, 2,119 of whom are in Italy and has a turnover of € 2 billion 229 million. Chiesi’s business comprises 30 affiliates, 7 research centres, 3 production sites and a commercial presence in a total of 90 countries. These results are confirmation…
Company sponsors #wewearstripes social media campaign calling on participants to share photos to express support for people affected by rare diseases Company to light up offices around the world including Italy, the United States, and Canada Parma (Italy) - February 26, 2021 - Chiesi Global Rare…
Trimbow is the first extrafine formulation fixed triple combination therapy in a single inhaler to be approved for use in appropriate asthma patients. 1,2 This follows the 2017 approval of this therapeutic option for the treatment of appropriate moderate to severe chronic obstructive pulmonary…
The Group’s head office in Parma: a new facility housing more than 540 employees. People, Innovation, Sustainability form the foundations on which the headquarters were built. Designed on the basis of a new vision of the workplace as a shared space, centred on respect for environment and energy…
At infermieriavisoaperto.it shots taken by photographer Settimio Benedusi visually tell the story of nursing professionals who are fundamental to our healthcare service. This virtual photographic exhibition was promoted and set up by the Chiesi Group under the patronage of the FNOPI, the National…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
